ArticleDiagnostics (Basel, Switzerland)2026
Evaluation of the Proliferation Marker Ki-67 for Improved Risk Stratification of Prostate Cancer Patients Under Active Surveillance.
Viktoria Schütz, Maresa Rothermel, Adam Kaczorowski, Svenja Dieffenbacher, Sarah Heike Böning, Constantin Schwab, Albrecht Stenzinger, Johannes Huber, Anette Duensing, Markus Hohenfellner and 1 more
Abstract read
In one paragraphArticle in Diagnostics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Viktoria SchützDepartment of Urology, Heidelberg University Hospital, Im Neuenheimer Feld 420, 69120 Heidelberg, Germany.ORCID 0000-0003-2179-747X Maresa RothermelDepartment of Urology, Heidelberg University Hospital, Im Neuenheimer Feld 420, 69120 Heidelberg, Germany.
Adam KaczorowskiMolecular Urooncology, Department of Urology, Heidelberg University Hospital, Im Neuenheimer Feld 517, 69120 Heidelberg, Germany.
Svenja DieffenbacherDepartment of Urology, Heidelberg University Hospital, Im Neuenheimer Feld 420, 69120 Heidelberg, Germany.
Sarah Heike BöningMolecular Urooncology, Department of Urology, Heidelberg University Hospital, Im Neuenheimer Feld 517, 69120 Heidelberg, Germany.
Constantin SchwabInstitute of Pathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, 69120 Heidelberg, Germany.ORCID 0000-0002-0979-2943 Albrecht StenzingerInstitute of Pathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, 69120 Heidelberg, Germany.
Johannes HuberDepartment of Urology, Heidelberg University Hospital, Im Neuenheimer Feld 420, 69120 Heidelberg, Germany.ORCID 0000-0001-7243-8958 Anette DuensingDepartment of Urology, Heidelberg University Hospital, Im Neuenheimer Feld 420, 69120 Heidelberg, Germany.ORCID 0000-0002-0168-4067 Markus HohenfellnerDepartment of Urology, Heidelberg University Hospital, Im Neuenheimer Feld 420, 69120 Heidelberg, Germany.
Stefan DuensingDepartment of Urology, Heidelberg University Hospital, Im Neuenheimer Feld 420, 69120 Heidelberg, Germany.
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
active surveillanceKi-67prostate cancerrisk stratificationtumor marker
Identifiers
PMID41975689
PMCPMC13072387
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390